A phase I trial of EC-2629
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
Price : $35 *
At a glance
- Drugs EC 2629 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 08 Aug 2017 According to an Endocyte media release, the company has filed an Investigational New Drug (IND) application for EC2629.
- 20 Mar 2017 New trial record
- 10 Mar 2017 According to an Endocyte media release, this trial is expected to initiate enrollment in the second half of 2017.